Zentalis Pharmaceuticals Inc (ZNTL)

$2.24 -0.15 (-6.28%)
Market Cap 170.32M
Revenue (ttm) 0.00
Net Income (ttm) -292.19M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 3,160,300
Avg Vol 1,341,204
Day's Range N/A - N/A
Shares Out 71.27M
Stochastic %K 7%
Beta 1.86
Analysts Sell
Price Target $9.60

Latest News on ZNTL

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Jan 9, 2025, 7:00 AM EST - 8 days ago

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 2, 2025, 4:53 PM EST - 15 days ago

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Announces Key Management Appointments

Dec 12, 2024, 7:00 AM EST - 5 weeks ago

Zentalis Pharmaceuticals Announces Key Management Appointments

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

Nov 21, 2024, 1:14 PM EST - 2 months ago

Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

Oct 7, 2024, 2:03 PM EDT - 3 months ago

FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Sep 16, 2024, 9:00 AM EDT - 4 months ago

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Sep 16, 2024, 7:00 AM EDT - 4 months ago

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Sep 9, 2024, 7:00 AM EDT - 4 months ago

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Aug 19, 2024, 4:55 PM EDT - 5 months ago

Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 5 months ago

Investors In Zentalis Pharmaceuticals Inc Encouraged To Participate In Fraud Investigation With The Schall Law Firm

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 5 months ago

Shareholders With Losses In Zentalis Pharmaceuticals Inc Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Investors Asked To Partake In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Stockholders Invited To Join In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 15, 2024, 4:00 PM EDT - 5 months ago

Zentalis Pharmaceuticals, Inc. (ZNTL) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Investors Welcome To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Aug 14, 2024, 1:00 AM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Aug 12, 2024, 11:15 PM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Investors Invited To Join Fraud Investigation With Schall Law Firm

Zentalis Pharmaceuticals Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 9:15 PM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Investors Can Participate In Fraud Investigation With The Schall Law Firm

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

Aug 9, 2024, 7:00 AM EDT - 5 months ago

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

Zentalis Pharmaceuticals Inc Investors Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 4:45 PM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Investors Eligible To Join Fraud Investigation With The Schall Law Firm

Zentalis Pharmaceuticals Inc Investors May Join A Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 11:30 PM EDT - 5 months ago

Zentalis Pharmaceuticals Inc Investors May Join A Fraud Investigation With The Schall Law Firm